Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4.
This report describes a patient with metastatic malignant melanoma treated with recombinant human interleukin 4 who developed vitiligo and severe Graves' Disease after therapy. The patient has experienced complete remission of melanoma for 49+ months. The association of antitumor response, vitiligo and thyroid disorders is reviewed.